BM involvement also appeared to impact prognosis of CD5+ DLBCL significantly in the training set (Figures 1J-K, which however was not confirmed in the validation set), and development of CNS relapse (0% at diagnosis, 8.3% after treatment) was remarkable for CD5+ DLBCL. Here, CD5 is linked to diffuse large B-cell lymphoma.